Evolution of Cancer Biomarker and its Therapeutic Drug

Migmar Tsamchoe; Tenzin Kungyal

Abstract

The trend to develop personalized medicine in targeting the defective genes/proteins and its pathways have become a promising approach with a significant success rate seen so far. The causes of cancer vary from person to person. Mutation in a cancer-associated gene or causative gene such as EGFR, VEGF, mTOR etc will cause cancer and later metastasis but treatment has to be given by identifying the specific marker and targeting the defective protein. There are lots of drugs for cancer which is inhibiting the mutated kinases, oncogene and the most recent approach being the anticancer immunotherapy which has so far have least side effect and success in overall survival had let to undying search for novel drugs for the treatment of cancer. Therefore in this review, we have discussed the evolvement of cancer therapeutics targets, biomarkers, drugs which had helped in increasing overall survival rate.Keywords: Metastasis, angiogenesis, kinase inhibitor, immunotherapy, VEGFCite this ArticleMigmar Tsamchoe, Tenzin Kungyal. Evolution of Cancer Biomarker and its Therapeutic Drug. Research & Reviews: A Journal of Life Sciences. 2019; 9(3): 15–27p.